Management Strategies for POSEIDON Groups 3 and 4

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review


  • Thor Haahr
  • Carlos Dosouto, Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain -
  • ,
  • Carlo Alviggi, Consiglio Nazionale Delle Ricerche, Istituto per L'Endocrinologia e L'Oncologia Sperimentale, Naples, Italy.
  • ,
  • Sandro C Esteves, ANDROFERT-Andrology and Human Reproduction Clinic & University of Campinas (UNICAMP), Campinas, Brazil., Department of Surgery (Division of Urology), Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil.
  • ,
  • Peter Humaidan

In the POSEIDON classification, patients belonging to groups 3 and 4 share the same common feature of a poor ovarian reserve which independently of age renders them at high risk of a poor reproductive outcome. Overall, POSEIDON groups 1-4 constitute approximately 47% of patients attending assisted reproductive technology (ART) treatment. With the increasing delay in childbearing, POSEIDON group 4 seems to increase in numbers now in some centers constituting more than 50% of the total POSEIDON population, whereas group 3 patients constitute approximately 10%. Both POSEIDON groups 3 and 4 patients require special attention as regards pre-treatment strategy, ovarian stimulation, adjuvant treatment, and ovulation trigger strategy in order to optimize the probability of having at least one euploid blastocyst for transfer. Although more evidence is needed, recent advances seem to have increased the reproductive outcomes in the poor prognosis patient. The key to success is individualization in all steps of ART treatment. Herein, we review the recent evidence for the management of POSEIDON groups 3 and 4.

TidsskriftFrontiers in Endocrinology
Sider (fra-til)614
Antal sider11
StatusUdgivet - 11 sep. 2019

Bibliografisk note

Copyright © 2019 Haahr, Dosouto, Alviggi, Esteves and Humaidan.

Se relationer på Aarhus Universitet Citationsformater

ID: 169180269